1. 1260PAn open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma. (23rd October 2018) Authors: Saiag, P; Robert, C; Grob, J J; Mortier, L; Dereure, O; Lebbe, C; Mansard, S; Grange, F; Neidhardt, E-M; Lesimple, T; Machet, L; Bedane, C; Jeudy, G; Aubin, F; Dreno, B; Szenik, A; Denden, A; Dutriaux, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗